Holen Sie sich die Stockscreener-App
1.951
11.32%
-0.249
Schlusskurs vom Vortag:
$2.20
Offen:
$2
24-Stunden-Volumen:
335.86K
Relative Volume:
1.00
Marktkapitalisierung:
$2.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.1921
EPS:
-10.156
Netto-Cashflow:
$-11.09M
1W Leistung:
+12.13%
1M Leistung:
-22.27%
6M Leistung:
-69.04%
1J Leistung:
-71.33%
1-Tages-Spanne:
$1.895
$2.1656
1-Wochen-Bereich:
$1.57
$2.9699
52-Wochen-Spanne:
$1.53
$10.35
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Vergleichen Sie PHIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.951 | 2.22M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.60 | 105.21B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.37 | 78.48B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
635.63 | 37.55B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.28 | 31.19B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.00 | 27.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Phio Pharmaceuticals Corp. Announces Positive Safety Monitoring Committee Recommendation to continue to Third Dose Cohort in its Clinical Study of PH-762 - Marketscreener.com
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio Pharmaceuticals Announces $480K Direct Offering with Warrant Coverage to Boost Working Capital - StockTitan
Phio Pharmaceuticals Rallies Following Key Trial and Funding Updates - Stocks Telegraph
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
As FedEx plans to spin off freight, can it cut costs even more? - Yahoo Finance
Phio stock hits 52-week low at $2.13 amid market challenges - Investing.com
Phio Pharmaceuticals Raises $1.15M Through Strategic Direct Offering and Warrant Placement - StockTitan
Franklin Resources (BEN-N) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 - Newsfile
Phio Pharmaceuticals Reports Complete Tumor Clearance in Phase 1b Cancer Trial: Key Clinical Data Released - StockTitan
Fed is weighing impact of Trump's proposed tariffs, Powell signals - Yahoo Finance
It's 'critical' home builders 'ramp up production': NAR economist - Yahoo Finance
Wall Street awaits Fed rate cut, expecting cautious tone for 2025 - Yahoo Finance
Bitcoin, 'super-bullish' sentiment, Axon: Asking for a Trend - Yahoo Finance
TCW Sticks to Bond wager Despite Losses - Yahoo Finance
Tesla clinches another record high after new bullish price targets from Wall Street - Yahoo! Voices
Broadcom stock eases on post-earnings rally as Nvidia tumbles - Yahoo Finance
Inheritance & savings: Planning challenges for LGBTQ+ individuals - Yahoo Finance
2025 will be 'a renter's market.' Redfin economist explains why. - Yahoo Finance
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology - Yahoo Finance
US has a 'sickcare system,' not a healthcare system: Anomaly CEO - Yahoo Finance
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award - StockTitan
D.R. Horton (DHI-N) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals to Present at Renmark Financial Virtual Roadshow - StockTitan
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets - Yahoo Finance
Phio Pharmaceuticals Announces Completion of Enrollment in Second - The Kingston Whig-Standard
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study - Newsfile
Phio Pharmaceuticals Corp. (PHIO) Quarterly 10-Q Report - Quartzy
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Alberta Daily Herald Tribune
Phio Pharma Reports 100% Tumor Clearance in Phase 1b Trial, Cuts Q3 Net Loss by 46% | PHIO Stock News - StockTitan
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PHIO stock touches 52-week low at $2.38 amid market challenges - Investing.com
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
PHIOPhio Pharmaceuticals Corp. Latest Stock News & Market Updates - StockTitan
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Newsfile
IMAX Corporation (IMAX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th - Shoreline Beacon
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable - GlobeNewswire
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Nasdaq Financial 100 Index (IXF) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - StockTitan
Dry Age-Related Macular Degeneration Market to Reach USD 10.57 Billion by 2032 with 9.1% CAGR – SNS Insider - GlobeNewswire
Phio Pharmaceuticals presents novel cancer therapy data - Investing.com
Phio Pharmaceuticals presents novel cancer therapy data By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference - Newsfile
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 - The Kingston Whig-Standard
Tonix Pharma Enhances Drug Development with AI Partnership - Yahoo Finance
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - Knox Daily
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | President & CEO |
Jun 06 '24 |
Buy |
0.75 |
1,000 |
750 |
19,990 |
| Bitterman Robert J | President & CEO |
Feb 26 '24 |
Buy |
0.91 |
2,500 |
2,275 |
18,990 |
0.11%
2.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):